| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/17/2010 | CN101652134A Drug for preventing and/or treating fatty liver or nonalcoholic fatty liver disease |
| 02/17/2010 | CN101652133A Use of prodrugs of GABA analogs for treating diseases |
| 02/17/2010 | CN101652132A Pharmaceutical composition using aliskiren and avosentan |
| 02/17/2010 | CN101652131A N, n- dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same |
| 02/17/2010 | CN101652130A Novel use of hydroxytyrosol and olive extracts/concentrates containing it |
| 02/17/2010 | CN101648950A Tiotropium salts, pharmaceutical composition and uses thereof |
| 02/17/2010 | CN101648944A 病毒聚合酶抑制剂 Viral polymerase inhibitors |
| 02/17/2010 | CN101648941A 4-tetrazolyl-4phenylpiperidine derivatives for treating pain |
| 02/17/2010 | CN101647808A Pharmaceutical composition for treating respiratory diseases of livestock and poultry, preparation method thereof and application thereof |
| 02/17/2010 | CN101647807A Abamectin aqueous emulsion for aquaculture |
| 02/17/2010 | CN101647806A Composition for treating gallinaceous vibrio hepatitis and preparation method thereof |
| 02/17/2010 | CN101647805A Glucosamine chewable tablet used for relieving and preventing osteoarthritis and preparation method thereof |
| 02/17/2010 | CN101647804A Compound amoxicillin soluble powder for treating duck oromeningitis and preparation method thereof |
| 02/17/2010 | CN101647803A External-use medicine for treating burns |
| 02/17/2010 | CN101647802A 5,7-diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity and composition thereof |
| 02/17/2010 | CN101647801A Application of tetracyclic triterpenoids compound in preparing anti-angiogenic drugs |
| 02/17/2010 | CN101647800A Combination of cefuroxime sodium |
| 02/17/2010 | CN101647799A Stable artesunate amodiaquine hydrochloride compound tablet and preparation method thereof |
| 02/17/2010 | CN101647798A Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
| 02/17/2010 | CN101647797A Pharmaceutical composition containing Amlodipine besilate and valsartan and preparation method thereof |
| 02/17/2010 | CN101647796A Application of osthole in preparing anti-angiogenic drugs |
| 02/17/2010 | CN101647795A Application of Xyloketal B in preparation of medicine for treating radical damage disease |
| 02/17/2010 | CN101647794A Diffractive ring mangiferin in mango leaf and new application of mango leaf extract containing diffractive ring mangiferin |
| 02/17/2010 | CN101647793A Application of anacardic acid in preparing anti-angiogenic drugs |
| 02/17/2010 | CN101647792A Use of treprostinil to treat and prevent ischemic lesions |
| 02/17/2010 | CN101647791A Brain targeted anticancer medicine and preparation method thereof |
| 02/17/2010 | CN101647790A Application of triacontanol for preparing anti-cancer medicine |
| 02/17/2010 | CN100590133C Growth hormone and serum albumni recombinant fusion protein |
| 02/17/2010 | CN100590124C Tricyclic androgen receptor modulator compounds and method |
| 02/17/2010 | CN100590118C Novel style heterocyclic compound as insulin-like growth factors first type acceptor inhibitor |
| 02/17/2010 | CN100589812C Plant worms mycelium extracat fraction and composition for oral intake |
| 02/17/2010 | CN100589809C Quaternised ammonium cyclodextrin compounds |
| 02/17/2010 | CN100589808C Gel agent containing centella general glycoside and sodium hyaluronate, its preparation method and uses |
| 02/17/2010 | CN100589807C Compound and its processing technology for compound sulfamonomethoxine sodium injection |
| 02/17/2010 | CN100589806C Use of steroid derivatives for the treatment of angiotensin II related disease e.g. cardiovascular and proliferative disorders |
| 02/17/2010 | CN100589805C External preparation of Levocetirizine hydrochloric acid |
| 02/17/2010 | CN100589804C Pharmaceutical composition containing milrinone |
| 02/17/2010 | CN100589803C Aryl-pyridine derivatives |
| 02/17/2010 | CN100589802C Pharmaceutical formulation of the sodium salt of telmisartan |
| 02/17/2010 | CN100589801C Spray-dried granules containing pranlukast and processes for the preparation thereof |
| 02/17/2010 | CN100589800C Chinese medicine preparation of total coumarins extract from peu cedanum praeruptorum dunn, and its preparing method and use |
| 02/17/2010 | CN100589799C Method of extracting flavone substance and ellagic acid from pomegranate blossom |
| 02/17/2010 | CN100589798C Medicinal composition containing nitrate esters for treating ventricular hypertrophy or myocardial fibrosis |
| 02/17/2010 | CN100589797C Extended release venlafaxine formulation |
| 02/17/2010 | CN100589796C Highly efficient delivery of large therapeutic mass aerosol |
| 02/16/2010 | USRE41134 Slow release vehicles for minimizing skin irritancy of topical compositions |
| 02/16/2010 | US7663000 Quinoneimines of malonic acid diamides |
| 02/16/2010 | US7662995 1-(2-Fluoro-4'-trifluoromethylbiphenyl-4-yl)cyclopropanecarboxylic acid, for example; treatment and/or prevention of Alzheimer's disease; inhibiting the release of A beta 42 peptide thereby being able to modulate gamma-secretase activity without affecting other important metabolic processes |
| 02/16/2010 | US7662988 Pesticides; 4-propargyl-2,3,5,6-tetrafluorobenzyl (1R)-trans-3-(2-cyano-1-propenyl)-2,2-dimethylcyclopropanecarboxylate |
| 02/16/2010 | US7662977 Such as 2-cationic amino-4-oxo-chromene derivatives; water solubility, pharmacokinetics; reduced side effects; anticancer agents |
| 02/16/2010 | US7662976 Triptolide derivatives for modulation of apoptosis and immunosuppression |
| 02/16/2010 | US7662974 Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same |
| 02/16/2010 | US7662972 Insecticidal and acaricidal activity for many agricultural insect pests, spider mites; endo- or ecto-parasiticide for mammals or birds; veterinary medicine; environmentally friendly |
| 02/16/2010 | US7662967 3-(2',2'-Dimethylpropanoylamino)tetrahydropyridin-2-one for prevention or treatment of inflammatory disorders, autoimmune diseases |
| 02/16/2010 | US7662966 For example, 5-tert-Butyl-2-{2-[4-(1-methyl-piperidin-4-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; use in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions |
| 02/16/2010 | US7662958 e.g. N-[3-{1-[(cyclobutyl)amino]-4-hydroxy-2-oxo-1,2-dihydro-quinolin -3-yl}-1,1-dioxo-1,4-dihydro-1 lambda 6-thieno[2,3-e][1,2,4]thiadiazin-7-yl)methyl]methane-sulfonamide; viricides for infections caused by an RNA-containing virus; hepatitis C virus (HCV) polymerase inhibitor; liver cirrhosis |
| 02/16/2010 | US7662956 Ethyl[7-chloro-5-(2-chloroprene)-1-isobutyl-2-oxo-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-acetate; dyslipidaemia, arteriosclerosis, restenosis and ischemia |
| 02/16/2010 | US7662948 Antisense oligonucleotides against VR1 |
| 02/16/2010 | US7662938 2′-fluoronucleosides |
| 02/16/2010 | US7662933 Pegylated granulocyte colony stimulating factor (G-CSF) to treat a hematopoietic disorder related to reduced neutrophil count, such as infectious disease, sepsis, or a result of radiotherapy or chemotherapy |
| 02/16/2010 | US7662929 Enzyme is a drug target; cancer, inflammatory diseases such as psoriasis |
| 02/16/2010 | US7662864 Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent |
| 02/16/2010 | US7662863 Therapeutic agent for the use in reducing alcohol intoxication and reducing or eliminating the negative side effects associated with alcohol ingestion |
| 02/16/2010 | US7662861 Compositions containing prodrugs of florfenicol and methods of use |
| 02/16/2010 | US7662860 Cinanserin analogs were synthesized and tested at molecular and viral levels and were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection |
| 02/16/2010 | US7662859 Biuret-containing moiety with triiodated phenyl groups attached; N,N,N'-tris-(3-{acetyl-[3,5-bis-(2,3-dihydroxy-propyl-carbamoyl)-2,4,6-triiodo-phenyl]-amino}-2-hydroxy-propyl)-dicarbonimidic diamide for example; X-ray imaging; synthesis by reacting e.g. triglycidyl isocyanurate in one pot process |
| 02/16/2010 | US7662858 Orally administering diclofenac potassium in liquid dispersible formulation over 24 hours; for bunion surgery |
| 02/16/2010 | US7662857 Diagnostic agents for pancreatic exocrine function |
| 02/16/2010 | US7662856 Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine |
| 02/16/2010 | US7662855 For treatment of skin disorders (acne); solubilized in alcohol |
| 02/16/2010 | US7662854 HIF hydroxylase inhibitors |
| 02/16/2010 | US7662853 Monoacetyldiacylglycerol derivative for the treatment of sepsis |
| 02/16/2010 | US7662852 Compounds and preparations having antiviral effect |
| 02/16/2010 | US7662851 Use of specific cyklolignans |
| 02/16/2010 | US7662850 Therapeutic substituted chlorocyclopentanols |
| 02/16/2010 | US7662849 N-cyanomethyl-2R-[(benzenesulfonyliminomethyl)amino]-3-(2-difluoromethoxyphenylmethanesulfonyl)-propionamide; treating autoimmune disorders |
| 02/16/2010 | US7662848 Process for the preparation of Fluvastatin Sodium salt |
| 02/16/2010 | US7662847 Myelodysplastic syndrome, Parkinson*s disease, multiple sclerosis, AIDS, chronic obstructive pulmonary disease, acquired respiratory distress; analgesics, angiogenesis inhibitors; anticarcinogenic and antitumor agents; phopshodiesterase, tumor necrosis factor and matrix metalloproteinase inhibitors |
| 02/16/2010 | US7662846 Selective spirocyclic glucocorticoid receptor modulators |
| 02/16/2010 | US7662845 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 |
| 02/16/2010 | US7662844 1-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxymethyl]-cyclopropanecarboxylic acid; enzyme inhibitor; for the treatment of various diseases that respond to treatment by retinoids and by naturally occurring retinoic acid |
| 02/16/2010 | US7662843 Isoxazoline compounds having MIF antagonist activity |
| 02/16/2010 | US7662842 (4R)-2-(4-methoxyphenyl)-N-octadecylthiazolidine-4-carboxamide; antiacarcinogenic agent for destroying a melanoma cell |
| 02/16/2010 | US7662841 Imidazothiazole derivatives and process for producing the same |
| 02/16/2010 | US7662840 4-{5-[4-(5-Isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine or N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine (DW-1350); a leukotriene-B4 receptor antangonist; inhibiting osteoclastic bone absorption |
| 02/16/2010 | US7662839 EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders; e.g. {4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl}-acetic acid |
| 02/16/2010 | US7662838 containing N-(5-adamantane-1-yl-methoxy-pentyl)- group; for treatment of insulin resistance, hyperpigmentation and/or inflammatory processes in skin, fungal disease, overweight and obesity, or microbacterial infection |
| 02/16/2010 | US7662837 Inhibitors of c-fms kinase |
| 02/16/2010 | US7662836 Indazole having analgesic activity |
| 02/16/2010 | US7662835 Methods of treating allergic reactions using an anhydrous form of antihistaminic piperidine derivatives |
| 02/16/2010 | US7662834 Methods of 1H-indol-3-yl-2-oxoacetamide compounds |
| 02/16/2010 | US7662833 metalloproteinases inhibitor, particular Peptide Deformylase (Pdf) inhibitor; antibiotic; e.g. 2-(6-fluoro-imidazo[1,2-a]pyridin-3-ylamino)-N-hydroxy-acetamide |
| 02/16/2010 | US7662832 Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof |
| 02/16/2010 | US7662831 N-5,6,9,10,11,12-hexahydro-4H,8H-cyclohepta[4,5]pyrrolo[3,2,1-ij]quinolin-2-yl-3,3-dimethylbutanamide; for treating cardiovascular disorders, nervous system disorders e.g epilepsy, episodic ataxia type 1, paroxysmal dyskinesia, neurodegenerative spincerebrallar ataxia, Parkinson's disease |
| 02/16/2010 | US7662830 2-{4-[6-(3-Chloro-4-fluoro-phenyl)-2-morpholin-4-yl-pyrimidin-4-yl]-piperazin-1-yl}-nicotinic acid ethyl ester; 5-Methyl-6-{4-[2-(2-methyl-pyrrolidin-1-yl)-6-phenyl-pyrimidin-4-yl]-piperazin-1-yl}-nicotinic acid; treating conditions related to capsaicin receptor activation; neurophathic pain |
| 02/16/2010 | US7662829 Methods, compositions, and kits for organ protection during systemic anticancer therapy |
| 02/16/2010 | US7662828 Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds |
| 02/16/2010 | US7662827 Pyrazole derivatives having tyrosine kinase inhibitory activity |
| 02/16/2010 | US7662826 Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same |
| 02/16/2010 | US7662825 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma |